![]() |
|||||||||||||||||||||||||
Recent Research Breakthroughs
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
Richard Anderson |
|
|
J Cell Biol. 2007 Jan 29;176(3):343-53. Assembly of E-cadherin-based adherens junctions (AJ) is obligatory for establishment of polarized epithelia and plays a key role in repressing the invasiveness of many carcinomas. Here we show that type Igamma phosphatidylinositol phosphate kinase (PIPKIgamma) directly binds to E-cadherin and modulates E-cadherin trafficking. PIPKIgamma also interacts with the mu subunits of clathrin adaptor protein (AP) complexes and acts as a signalling scaffold that links AP complexes to E-cadherin. Depletion of PIPKIgamma or disruption of PIPKIgamma binding to either E-cadherin or AP complexes results in defects in E-cadherin transport and blocks AJ assembly. An E-cadherin germline mutation that loses PIPKIgamma binding and shows disrupted basolateral membrane targeting no longer forms AJs and leads to hereditary gastric cancers. These combined results reveal a novel mechanism where PIPKIgamma serves as both a scaffold, which links E-cadherin to AP complexes and the trafficking machinery, and a regulator of trafficking events via the spatial generation of phosphatidylinositol-4,5-bisphosphate. Ling K, Bairstow SF, Carbonara C, Turbin DA, Huntsman DG, Anderson RA. |
||
![]() |
Emery Bresnick
|
|
|
Mol Cell Biol. 2007 Jan 12 Wu J, Bresnick EH. University of Wisconsin School of Medicine, Department of Pharmacology, 1300 University Avenue, Madison, WI 53706. |
||
![]() |
Emery Bresnick |
|
|
Journal of Cell Biology, 2006 Saumen Pal, Jing Wu, Justin K. Murray, Samuel H. Gellman, Michele A. Wozniak, Patricia J. Keely, Meghan E. Boyer, Timothy M. Gomez, Sean M. Hasso, John F. Fallon, and Emery H. Bresnick |
||
Ed Chapman |
||
|
Nature (in press). (2006) Structural basis of receptor recognition by botulinum neurotoxin B. Botulinum neurotoxins (BoNTs) are potent bacterial toxins that cause paralysis at femtomolar concentrations by blocking neurotransmitter release. A 'double receptor' model has been proposed in which BoNTs recognize nerve terminals via interactions with both gangliosides and protein receptors that mediate their entry. Of seven BoNTs (subtypes A - G), the putative receptors for BoNT/A, BoNT/B, and BoNT/G have been indentified, but the molecular details that govern recognition remain undefined. Here we report the crystal structure of full-length BoNT/B in complex with the synaptotagmin II (Syt-II) recognition domain at 2.6 A resolution. The structure of the complex reveals that Syt-II forms a short helix that binds to a hydrophobic groove within the binding domain of BoNT/B. In addition, mutagenesis of amino acid residues within this interface on Syt-II affects binding of BoNT/B. Structural and sequence analysis reveals that this hydrophobic groove is conserved in the BoNT/G and BoNT/B subtypes, but varies in other clostridial neurotoxins. Futhermore, molecular docking studies using the ganglioside GT1b indicate that its binding site is more extensive than previously proposed and might form contacts with both BoNT/B and synaptotagmin. The results provide structural insights into how BoNTs recognize protein receptors and reveal a promising target for blocking toxin-receptor recognition. *Chai, Q., *Arndt, J.W., *Dong, M., Tepp, W.H., Johnson, E.A., #Chapman, E.R. and #Stevens, R.C.. (2006). Structural basis of receptor recognition by botulinum neurotoxin B. Nature 444: 1096-1100. * equal contribution |
||
|
Science 312: 592-596. (2006) A Neuronal Receptor for Botulinum Toxin ("Perspective") - Science How the widely used botulinum
neurotoxin A (BoNT/A) recognizes and enters neurons is poorly understood.
We found that BoNT/A enters neurons by binding to the synaptic vesicle
protein SV2 (isoforms A, B, and C). Fragments of SV2 that harbor
the toxin interaction domain inhibited BoNT/A from binding to neurons.
BoNT/A binding to SV2A and SV2B knockout hippocampal neurons was
abolished and was restored by expressing SV2A, SV2B, or SV2C. Reduction
of SV2 expression in PC12 and Neuro-2a cells also inhibited entry
of BoNT/A, which could be restored by expressing SV2 isoforms. Finally,
mice that lacked an SV2 isoform (SV2B) displayed reduced sensitivity
to BoNT/A. Thus, SV2 acts as the protein receptor for BoNT/A. |
Ed ChapmanWisconsin
State Journal Article |
||
|
Proc. Natl. Acad. Sci. USA 101: 14701-14706. (2004). Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Dong, M., Goodnough,
M.C., Tepp, W.H., Johnson, E.A. and Chapman, E.R.. |
||
|
Ed ChapmanMeyer Jackson |
||
|
Transmembrane segments of syntaxin line the fusion pore of Ca2+-triggered exocytosis. Han, X., Wang, C.T., Bai, J., Chapman, E.R. and Jackson, M.B. The fusion pore of regulated exocytosis is a channel that connects and spans the vesicle and plasma membranes. The molecular composition of this important intermediate structure of exocytosis is unknown. Here, we found that mutations of some residues within the transmembrane segment of syntaxin (Syx), a plasma membrane protein essential for exocytosis, altered neurotransmitter flux through fusion pores and altered pore conductance. The residues that influenced fusion-pore flux lay along one face of an a-helical model. Thus, the fusion pore is formed at least in part by a circular arrangement of 5 to 8 Syx transmembrane segments in the plasma membrane. |
||
|
Shigeki Miyamoto |
||
|
Cell, Vol. 115, 1-20,
November 26, 2003, Copyright 2003 by Cell Press |
||
|
|
Edwin ChapmanMeyer JacksonThomas Martin |
|
| Exocytosisthe
release of the contents of a vesicleproceeds by two mechanisms1-6.
Full fusion occurs when the vesicle and plasma membranes merge. Alternatively, in what is termed kiss-and-run, vesicles can release transmitter during transient contacts with the plasma membrane. Little is known at the molecular level about how the choice between these two pathways is regulated. Here we report amperometric recordings of catecholamine efflux through individual fusion pores. Transfection with synaptotagmin (Syt) IV increased the frequency and duration of kiss-and-run events, but left their amplitude unchanged. Endogenous Syt IV, induced by forskolin treatment, had a similar effect. Full fusion was inhibited by mutation of a Ca2+ ligand in the C2A domain of Syt I; kiss-and-run was inhibited by mutation of a homologous Ca2+ ligand in the C2B domain of Syt IV. The Ca2+ sensitivity for full fusion was 5-fold higher with Syt I than Syt IV, but for kiss-and-run the Ca2+ sensitivities differed by a factor of only two. Syt thus regulates the choice between full fusion and kiss-and-run, with Ca2+ binding to the C2A and C2B domains playing an important role in this choice. |
||
![]() |
Emery BresnickGermany - "Innovations Report" United States - New release web site Spanish Medical Society of Anti-aging and Longevity |
|
|
from the University of Wisconsin Medical School Web site: Researchers Find Mechanism That May Determine Early BloodCell Fate Hematopoietic stem cells, the mother of all blood cells, face a fundamental dilemma in their lives. Each must either remain a hematopoietic stem cell (HSC) by renewing itself or it must transform into one of eight specialized types of blood cells, such as a red blood cell, a white blood cell or a platelet. Until recently, scientists didnt know how the essential cells, which exist in limited amounts in the body, decide which direction to go. Now, researchers in the University of Wisconsin Medical School Department of Pharmacology have found a mechanism that might determine what each HSC will be. The mechanism involves an unexpected interaction between two related proteins. |
||
![]() |
Timothy Kamp |
|